Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chen Katz

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2021
MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53Alyssa M Klein, Lynn Biderman, David Tong, et al.
Genes & Development|March 18, 2018
Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramersChen Katz, Ana Maria Low-Calle, Joshua H Choe, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 23, 2008
Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2Chen Katz, Hadar Benyamini, Shahar Rotem, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 22, 2012
Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stressSladana Bursać, Maja Cokarić Brdovčak, Martin Pfannkuchen, et al.
Frontiers in Immunology|December 28, 2023
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumorsShawn Iadonato, Yulia Ovechkina, Kurt Lustig, et al.
Frontiers in Immunology|February 7, 2024
Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumorsShawn Iadonato, Yulia Ovechkina, Kurt Lustig, et al.
Nature Structural & Molecular Biology|July 20, 2010
The C terminus of p53 binds the N-terminal domain of MDM2Masha V Poyurovsky, Chen Katz, Oleg Laptenko, et al.
Cancer Research|June 9, 2019
An <i>ERG</i> Enhancer-Based Reporter Identifies Leukemia Cells with Elevated Leukemogenic Potential Driven by ERG-USP9X Feed-Forward RegulationNasma Aqaqe, Muhammad Yassin, Abed Alkader Yassin, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Integrated strategy reveals the protein interface between cancer targets Bcl-2 and NAF-1Sagi Tamir, Shahar Rotem-Bamberger, Chen Katz, et al.
Cell Death & Disease|March 3, 2026
Mesenchymal stromal cells modulate survival and regeneration of human hematopoietic stem cells via PGE2/cAMP signalingSiva Sai Naga Anurag Muddineni, Chen Katz-Even, Adi Zipin-Roitman, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2021
MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53Alyssa M Klein, Lynn Biderman, David Tong, et al.
Genes & Development|March 18, 2018
Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramersChen Katz, Ana Maria Low-Calle, Joshua H Choe, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 23, 2008
Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2Chen Katz, Hadar Benyamini, Shahar Rotem, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 22, 2012
Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stressSladana Bursać, Maja Cokarić Brdovčak, Martin Pfannkuchen, et al.
Frontiers in Immunology|December 28, 2023
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumorsShawn Iadonato, Yulia Ovechkina, Kurt Lustig, et al.
Frontiers in Immunology|February 7, 2024
Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumorsShawn Iadonato, Yulia Ovechkina, Kurt Lustig, et al.
Nature Structural & Molecular Biology|July 20, 2010
The C terminus of p53 binds the N-terminal domain of MDM2Masha V Poyurovsky, Chen Katz, Oleg Laptenko, et al.
Cancer Research|June 9, 2019
An <i>ERG</i> Enhancer-Based Reporter Identifies Leukemia Cells with Elevated Leukemogenic Potential Driven by ERG-USP9X Feed-Forward RegulationNasma Aqaqe, Muhammad Yassin, Abed Alkader Yassin, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Integrated strategy reveals the protein interface between cancer targets Bcl-2 and NAF-1Sagi Tamir, Shahar Rotem-Bamberger, Chen Katz, et al.
Cell Death & Disease|March 3, 2026
Mesenchymal stromal cells modulate survival and regeneration of human hematopoietic stem cells via PGE2/cAMP signalingSiva Sai Naga Anurag Muddineni, Chen Katz-Even, Adi Zipin-Roitman, et al.
Pageof 4